Scientists Uncover Protein that Inhibits Coronaviruses
The research reveals that the LY6E protein impairs the coronavirus’ ability to initiate infection, which could lead to treatments for the illness.
20 Molecular Diagnostics Companies to Watch
Up-and-Coming Diagnostic Test Developers Emerge as Consolidation Thins the Field.
Orchid Launch Stirs Up PRS Debate
The company has begun marketing to consumers its PRS-based preconception test expected to be available later this year.
10 Liquid Biopsy Companies in the Money
10 privately-held diagnostics developers primarily focused on liquid biopsy tests, ranked by total money raised from venture capital firms.
ACE inhibitors and Angiotensin Receptor Blockers May Increase Mortality Rate In Elderly COVID-19 Patients
These highly prescribed medications change cell surface protein expression, which is particularly problematic in cells in the respiratory system—tissue that is vulnerable to targeting and attack by the COVID-19 virus.
Graphene Hydrogel Could Help mRNA Vaccine Target Cancer More Effectively
A specialized hydrogel can not only encapsulate and protect mRNA cancer vaccines from being broken down in the body, but can also target lymph nodes to activate immune cells, shows early stage research.
10 Countries in 100K Genome Club
These ten governments have committed funding for projects that will sequence a minimum of 100,000 citizens to spur genomic medicine
8 Companion Diagnostic Developers Making a Mark
If companion diagnostics (CDx) were people, they would be old enough to drink. The first CDx won FDA approval in 1998, when Dako Denmark...
COVID-19 Lung Damage Reduced in Patients Prescribed Fenofibrate, New Study Suggests
The results demonstrated that patients who were taking drugs to speed up the breakdown of fats in their lungs were recovering from lung infections caused by COVID-19 in a matter of days—with no mortality among these patients.
Coronavirus Replication Stopped in 48 Hours in Lab-Grown Cells by Anti-Parasitic Drug
The studies showed that the drug, ivermectin, started to become effective against SARS-CoV-2 in lab-grown cells within just a day and “could essentially remove all viral RNA by 48 hours,” researchers said.
